Ivonescimab plus paclitaxel for advanced stomach or esophageal cancer
Part of Cancer clinical trials.
This study tests a new combination of two drugs for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic stomach or gastroesophageal junction adenocarcinoma.
- You are between 18 and 75 years old.
- Your cancer has progressed after first-line treatment with a PD-1/PD-L1 inhibitor plus platinum-based chemotherapy.
- You have not received more than one line of systemic therapy for advanced disease.
- You are able to perform daily activities with minimal help (ECOG performance status 0-1).
- You have at least one measurable tumor lesion that can be assessed by imaging.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two experimental immunotherapies (AK104 and AK109) with a standard chemo drug (paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has grown after initial treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer better than chemo alone.
This study tests a combination of two drugs (paclitaxel, a chemotherapy, and apatinib, a targeted drug) with an immunotherapy (adebrelimab) for advanced stomach cancer. It may be an option if you've already tried immunotherapy and need a new approach.
This study tests two different treatment options for advanced stomach or gastroesophageal junction cancer that has grown after earlier chemotherapy. One option combines a targeted therapy (ramucirumab) with a chemotherapy pill (trifluridine/tipiracil), and the other is a standard chemotherapy drug (paclitaxel). The goal is to see which approach works better for people whose cancer has progressed, with the hope of improving outcomes.
This study tests new drug combinations for people with advanced stomach or esophageal cancer that worsened after first treatment. It aims to find better options for those whose tumors lack HER2.
This study tests a new combination of drugs (apatinib, nab-paclitaxel, and possibly adebrelimab) for advanced stomach or gastroesophageal junction cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests a new way to deliver chemotherapy directly into the belly for stomach cancer that has spread to the lining of the abdomen (peritoneal metastases). It also combines two standard chemotherapy drugs. The goal is to see if this approach can help people whose cancer progressed after first treatment.
Hear when a new Gastric (Cardia, Body) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.